The objective of the present study was to address this limitation with a highly potent antitumor agent whose clinical use is presently not possible, but which could be made feasible if the compound were to be successfully delivered by liposomes. Liposome-based delivery systems have been used to enhance drug efficacy and reduce toxicity. The most successful systems have been engineered for long circulation times and stable liposomal encapsulation of the active drug. We successfully encapsulated staurosporine into PEG liposomes using a novel gradient method. Our confirmatory tests showed high encapsulation efficiency and a favorable drug release profile and serum stability. We also showed the favorable clinical potential of liposomal staurosporine in terms of anti-tumor potency with different glioblastoma cell lines in culture, radiation sensitization of glioblastoma lines, and anti-glioblastoma effects using an in vivo subcutaneous mouse model. This method can be used for encapsulation of different classes of drugs.

Encapsulation of staurosporine using a novel intraliposomal stabilization strategy: Therapeutic efficacy in glioma

243rd National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.